blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2086568

EP2086568 - ACTIVATED PROTEIN C VARIANTS WITH NORMAL CYTOPROTECTIVE ACTIVITY BUT REDUCED ANTICOAGULANT ACTIVITY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.05.2015
Database last updated on 29.10.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): MT
published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037 / US
[2014/28]
Former [2009/33]For all designated states
The Scrips Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037 / US
Inventor(s)01 / GRIFFIN, John H.
13924 Boquita Drive
Del Mar, California 92014 / US
02 / MOSNIER, Laurent O.
8950 Costa Verde Boulevard
San Diego, California 92122 / US
03 / GALE, Andrew J.
10174 Bolin Street
San Diego, California 92126 / US
 [2009/33]
Representative(s)Heare-Rowlands, Tanya
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
[N/P]
Former [2013/49]Heare, Tanya
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
Former [2009/33]Jump, Timothy John Simon, et al
Venner Shipley LLP 20 Little Britain London
EC1A 7DH / GB
Application number, filing date07868617.730.10.2007
[2009/33]
WO2007US82980
Priority number, dateUS2006058937130.10.2006         Original published format: US 589371
[2009/33]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008055145
Date:08.05.2008
Language:EN
[2008/19]
Type: A2 Application without search report 
No.:EP2086568
Date:12.08.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 08.05.2008 takes the place of the publication of the European patent application.
[2009/33]
Type: B1 Patent specification 
No.:EP2086568
Date:09.07.2014
Language:EN
[2014/28]
Search report(s)International search report - published on:US09.04.2009
(Supplementary) European search report - dispatched on:EP12.10.2010
ClassificationIPC:A61K38/48, C12N9/64, A61P43/00
[2013/42]
CPC:
A61K38/4866 (EP,US); A61P21/00 (EP); A61P25/00 (EP);
A61P25/02 (EP); A61P25/14 (EP); A61P25/16 (EP);
A61P25/28 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); C12N9/6464 (EP,US); C12Y304/21069 (EP,US) (-)
Former IPC [2010/45]A61K38/48, C12N9/50, C12N9/64
Former IPC [2009/33]A61K38/17, C12N9/50
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/33]
TitleGerman:AKTIVIERTE PROTEIN C-VARIANTEN MIT NORMALER ZYTOPROTEKTIVER AKTIVITÄT, ABER VERRINGERTER GERINNUNGSHEMMENDER AKTIVITÄT[2009/33]
English:ACTIVATED PROTEIN C VARIANTS WITH NORMAL CYTOPROTECTIVE ACTIVITY BUT REDUCED ANTICOAGULANT ACTIVITY[2009/33]
French:VARIANTES DE PROTÉINE C ACTIVÉE AVEC UNE ACTIVITÉ CYTOPROTECTRICE NORMALE MAIS UNE ACTIVITÉ ANTICOAGULANTE RÉDUITE[2009/33]
Entry into regional phase17.04.2009National basic fee paid 
17.04.2009Search fee paid 
17.04.2009Designation fee(s) paid 
17.04.2009Examination fee paid 
Examination procedure17.04.2009Examination requested  [2009/33]
02.06.2009Amendment by applicant (claims and/or description)
25.10.2010Despatch of a communication from the examining division (Time limit: M06)
04.05.2011Reply to a communication from the examining division
13.09.2013Cancellation of oral proceeding that was planned for 24.09.2013
24.09.2013Date of oral proceedings (cancelled)
07.10.2013Communication of intention to grant the patent
26.03.2014Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
29.05.2014Fee for grant paid
29.05.2014Fee for publishing/printing paid
29.05.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.10.2010
Opposition(s)10.04.2015No opposition filed within time limit [2015/25]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
29.05.2014Request for further processing filed
29.05.2014Full payment received (date of receipt of payment)
Request granted
10.06.2014Decision despatched
Fees paidRenewal fee
30.10.2009Renewal fee patent year 03
23.11.2010Renewal fee patent year 04
11.10.2011Renewal fee patent year 05
11.10.2012Renewal fee patent year 06
14.10.2013Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.10.201004   M06   Fee paid on   23.11.2010
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.10.2007
AT09.07.2014
BE09.07.2014
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
MT09.07.2014
PL09.07.2014
RO09.07.2014
SI09.07.2014
SK09.07.2014
TR09.07.2014
BG09.10.2014
GR10.10.2014
IE30.10.2014
LU30.10.2014
CH31.10.2014
LI31.10.2014
IS09.11.2014
PT10.11.2014
[2016/33]
Former [2016/32]HU30.10.2007
AT09.07.2014
BE09.07.2014
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
PL09.07.2014
RO09.07.2014
SI09.07.2014
SK09.07.2014
TR09.07.2014
BG09.10.2014
GR10.10.2014
IE30.10.2014
LU30.10.2014
CH31.10.2014
LI31.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/50]AT09.07.2014
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
PL09.07.2014
RO09.07.2014
SI09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
IE30.10.2014
LU30.10.2014
BE31.10.2014
CH31.10.2014
LI31.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/46]AT09.07.2014
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
PL09.07.2014
RO09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
IE30.10.2014
LU30.10.2014
BE31.10.2014
CH31.10.2014
LI31.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/33]AT09.07.2014
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
PL09.07.2014
RO09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
LU30.10.2014
BE31.10.2014
CH31.10.2014
LI31.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/30]AT09.07.2014
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
PL09.07.2014
RO09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
LU30.10.2014
BE31.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/27]AT09.07.2014
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
PL09.07.2014
RO09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
LU30.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/26]AT09.07.2014
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
PL09.07.2014
RO09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
LU30.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/23]AT09.07.2014
CY09.07.2014
CZ09.07.2014
EE09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
PL09.07.2014
RO09.07.2014
SK09.07.2014
BG09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/22]AT09.07.2014
CY09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
PL09.07.2014
RO09.07.2014
BG09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/12]AT09.07.2014
CY09.07.2014
FI09.07.2014
LT09.07.2014
LV09.07.2014
PL09.07.2014
BG09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/11]CY09.07.2014
FI09.07.2014
LT09.07.2014
PL09.07.2014
BG09.10.2014
GR10.10.2014
PT10.11.2014
Former [2015/10]FI09.07.2014
LT09.07.2014
BG09.10.2014
Former [2015/09]FI09.07.2014
LT09.07.2014
Former [2015/08]LT09.07.2014
Documents cited:Search[XI]WO2005007820  (SCRIPPS RESEARCH INST [US], et al) [X] 1-16 * claims 1-41 * * page 5, paragraph 0014 - page 6, paragraph 0018 * * figures 1-6 * * examples 1-5; tables 1,2 * [I] 1-16;
 [X]WO2004056309  (SOCRATECH L L C [US], et al) [X] 1-16 * figures 9a-9f * * page 17, paragraph 2 * * page 39, paragraph 2; claim 20 *;
 [Y]WO0156532  (SCRIPPS RESEARCH INST [US], et al) [Y] 1-16 * example 3; claims 1-20 *;
 [XDI]  - MOSNIER LAURENT O ET AL, "Activated protein C variants with normal cytoprotective but reduced anticoagulant activity", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US LNKD- DOI:10.1182/BLOOD-2004-01-0110, (20040915), vol. 104, no. 6, ISSN 0006-4971, pages 1740 - 1744, XP002506855 [XD] 1-16 * table 1 * * page 1743, column r, paragraphs 2-3 * * abstract * * page 1744, column l, paragraph 2 - column r, paragraph 1 * [I] 1-16

DOI:   http://dx.doi.org/10.1182/BLOOD-2004-01-0110
 [XDI]  - GALE ANDREW J ET AL, "Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.M204363200, vol. 277, no. 32, ISSN 0021-9258, (20020809), pages 28836 - 28840, (20020612), XP002532145 [XD] 1-16 * figures 2,3,4; table 1 * * page 28839, column r, paragraph 2 - page 28840, column r, paragraph 3 * [I] 1-16

DOI:   http://dx.doi.org/10.1074/JBC.M204363200
 [Y]  - SHIBATA M ET AL, "ANTI-INFLAMMATORY, ANTITHROMBOTIC, AND NEUROPROTECTIVE EFFECTS OF ACTIVATED PROTEIN C IN A MURINE MODEL OF FOCAL ISCHEMIC STROKE", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, (20010401), vol. 103, ISSN 0009-7322, pages 1799 - 1805, XP002941848 [Y] 1-16 * abstract *
 [AD]  - MOSNIER LAURENT O ET AL, "Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB LNKD- DOI:10.1042/BJ20030341, (20030701), vol. 373, no. Pt 1, ISSN 0264-6021, pages 65 - 70, XP002532146 [AD] 1-16 * page 66, column r, paragraph 2 *

DOI:   http://dx.doi.org/10.1042/BJ20030341
International search[Y]  - GALE ET AL., "Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C.", J. BIOL. CHEM., (200206), vol. 277, no. 32, pages 28836 - 28840, XP002532145

DOI:   http://dx.doi.org/10.1074/JBC.M204363200
 [Y]  - MOSNIER ET AL., "Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-I and endothelial cell protein C receptor.", BIOCHEM. J., (2003), vol. 373, pages 65 - 70, XP002532146

DOI:   http://dx.doi.org/10.1042/BJ20030341
 [Y]  - RIEWALD ET AL., "Activation of endothelial cell protease activated receptor I by the protein C pathway.", SCIENCE., (2002), vol. 296, pages 1880 - 1882, XP002989623

DOI:   http://dx.doi.org/10.1126/science.1071699
by applicantUS4775624
 US4981952
 US6037322
 US5084274
    - BERNARD ET AL., NEW ENGL. J. MED., (2001), vol. 344, pages 699 - 709
    - WARREN ET AL., JAMA, (2001), vol. 286, pages 1869 - 878
    - ABRAHAM ET AL., CRIT. CARE MED., vol. 29, pages 2081 - 2089
    - HOTCHKISS; KARL, NEJM, (2003), vol. 348, pages 138 - 150
    - RUSSELL, NEW ENGL. J. MED., (2006), vol. 355, no. 16, pages 1699 - 713
    - ROSING; TANS, THROMB HAEMOST, (1997), vol. 78, pages 427 - 433
    - KALAFATIS; MANN, J. BIOL. CHEM., (1993), vol. 268, pages 27246 - 57
    - NORSTROM ET AL., J. BIOL. CHEM., (2003), vol. 278, pages 24904 - 1133
    - NICOLAES ET AL., J. BIOL. CHEM., (1995), vol. 270, pages 21158 - 66
    - GALE ET AL., BLOOD, (2000), vol. 96, pages 585 - 593
    - GALE ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 28836 - 28840
    - FRIEDRICH ET AL., J. BIOL. CHEM., (2001), vol. 276, pages 23105 - 08
    - KNOBE ET AL., PROTEINS, (1999), vol. 35, pages L218 - 234
 WO2003US38764
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.